GLP-1: Understanding Its Role Beyond the Satiety Signal

GLP-1: The Satiety Signal Everyone Might Be Oversimplifying

by Laurent Glatz – for Athletic Carnivore

GLP-1 is often hailed as a revolution against obesity, diabetes, cravings, fatty liver, sleep apnea, and perhaps even certain addictions or neurodegenerative diseases. This is precisely where the topic becomes dangerous to oversimplify. Because between biological reality, the impressive results of medications, research hopes, and marketing turning a hormone into a miracle solution, many risk missing the real question: what was their body already trying to signal before we artificially amplified this signal?

GLP-1, or glucagon-like peptide-1, is primarily an incretin hormone. It is secreted notably by the intestine after a meal. Its role is not to “make you lose weight” in a simplistic sense. Its role is to participate in coordination: informing the pancreas, brain, stomach, and metabolism that food intake has just occurred. It stimulates insulin secretion when glucose rises, suppresses glucagon when unnecessary, slows gastric emptying, and acts on certain brain circuits involved in satiety. GLP-1 receptor agonists, like semaglutide, mimic or prolong this signal, while newer molecules such as tirzepatide or retatrutide add other hormonal pathways, like GIP or glucagon. A review in the New England Journal of Medicine summarizes this foundation: these drugs improve glycemia, reduce appetite, slow gastric emptying, and exert metabolic effects beyond mere weight loss.

The first reality is that GLP-1 works. Not magically, but physiologically. In many patients with type 2 diabetes, obesity, or metabolic complications, GLP-1 agonists can reduce weight, improve glycated hemoglobin, lower certain cardiovascular risks, and slow progression of some kidney damage. They are no longer just “modern appetite suppressants.” Large trials have shifted the conversation: it’s no longer just about aesthetics or the scale, but about cardio-metabolic trajectory. Recent data confirm cardiovascular and renal benefits in high-risk populations, although the magnitude depends on the individual’s condition, the medication, the initial disease, and treatment adherence.

But the second, less comfortable reality is that GLP-1 does not necessarily fix the root cause of the dysfunction. It powerfully modifies signals. It can calm hunger. It can make dietary restriction easier. It can reduce food obsession. It can lower weight. But if the underlying terrain remains the same—disrupted sleep, chronic stress, ultra-processed food, low muscle mass, longstanding insulin resistance, insufficient protein, fragile digestion, lack of appropriate training—then the question becomes more complex: have we restored function, or merely temporarily forced a signal that had become unreadable?

This is where myths begin.

The first myth is believing that GLP-1 “melts fat” directly. In reality, it mainly helps reduce food intake by enhancing satiety, decreasing appetite, slowing gastric emptying, and improving some glycemic parameters. Weight loss then results from a changed energy balance, but in a more favorable hormonal context. This is not a mere vocabulary nuance. It’s a major difference. If a person eats less because their brain finally receives a stronger satiety signal, they can lose weight. But if this loss occurs with too little protein, insufficient muscle resistance training, and poor recovery, part of the lost mass may be lean tissue. Recent reviews remind us that side effects are mostly gastrointestinal, but loss of muscle and bone mass is a serious concern.

The second myth is believing these medications replace a dietary strategy. They can reduce appetite, but they don’t choose for you what builds your body. They can diminish cravings, but they don’t guarantee a diet rich in protein, micronutrients, and truly satiating foods. This is where the carnivore or low-carb logic becomes interesting—not as an automatic opposition to GLP-1, but as a lens. A diet centered on animal products, sufficiently protein-rich, low in processed foods, and more glycemically stable can already clarify hunger, satiety, and energy signals for some people. The problem is not to say carnivore replaces medical treatment. The problem is to understand that the medication acts on a signal already influenced by diet, sleep, stress, and physical activity.

The third myth is believing that if GLP-1 works, then the problem was necessarily a lack of willpower. This may be the most harmful error. Many people who lose weight on GLP-1 agonists discover for the first time what it means not to be dominated by hunger, food obsession, or compulsions. This does not prove they were weak before. It shows that their satiety system, dopamine, glycemia, stress, or food environment could produce internal pressure far beyond what moralistic advice can grasp. When the food noise quiets, some realize the problem was not only psychological. It was also biological.

But the reverse is also true: the fact that a medication helps does not mean all biology is repaired. It can mask lifestyle errors. It can reduce appetite to the point of under-eating. It can improve the scale number while leaving the person tired, less muscular, less performant, or dependent on an external lever. That’s why the real question is not just: “Does GLP-1 cause weight loss?” The real question is: “What exactly is the person losing, what are they preserving, and what terrain are they building during this loss?”

Current research broadens the debate further. GLP-1 is no longer studied only in diabetes and obesity. Recent programs explore cardiovascular diseases, kidneys, MASH—the former NASH, i.e., metabolic steatohepatitis—obstructive sleep apnea, certain joint pains, addictions, inflammatory disorders, and neurodegenerative diseases. The FDA approved tirzepatide for moderate to severe obstructive sleep apnea in obese adults in December 2024, and semaglutide for MASH with moderate to advanced fibrosis in August 2025.

This is a reality: the field is expanding. But it’s also an area where caution is needed. In sleep apnea, a significant part of the benefit may come from weight loss and reduced mechanical load, even if other metabolic mechanisms are possible. In MASH, improvements in weight, insulin, inflammation, and liver metabolism form a coherent whole. In kidneys and heart, effects are not always reducible to weight, as inflammation, endothelium, insulin, blood pressure, and albuminuria may also play roles. But in all cases, the same rule applies: an average result in a trial does not yet tell how your body, you, will respond.

Research in 2026 also shows the arrival of a new generation of molecules. Retatrutide, a triple GIP/GLP-1/glucagon agonist, demonstrated in TRIUMPH-1 an average body weight loss of 28.3% at 80 weeks at a 12 mg dose, with 45.3% of participants achieving at least 30% weight loss. This is considerable, approaching responses historically associated with bariatric surgery. But this efficacy comes with a major question: the more powerful the tool, the more precise the surrounding strategy must be. Losing a lot of weight is not the same as rebuilding a solid metabolism.

This point is central. Rapid weight loss can improve glycemia, blood pressure, apnea, pain, mobility, and some inflammatory markers. But it can also reveal or worsen other vulnerabilities if poorly managed: muscle wasting, fatigue, performance decline, nausea, constipation, food aversion, insufficient protein intake, weight regain after stopping, or psychological dependence on the medication. This is not an argument against GLP-1. It’s an argument against using them as shortcuts without reading the terrain.

Safety is another area of confusion. Digestive effects—nausea, vomiting, diarrhea, constipation, slowed gastric emptying—are known. Some tolerate them very well, others much less. Slowed gastric emptying can be useful for satiety but problematic for someone already prone to digestive heaviness, reflux, constipation, or suspected gastroparesis. The issue of mood and suicidal thoughts has also been highly publicized. In April 2026, the FDA requested removal of warnings about risk of suicidal behaviors or thoughts for certain GLP-1 agonists used in obesity after a review found no increased risk. This does not mean individual experiences should be ignored. It means the generalized causal signal was not confirmed in this evaluation.

Another myth is believing GLP-1 is a “comfort” treatment. This view is too narrow. In someone with severe obesity, diabetes, MASH, sleep apnea, kidney disease, or high cardiovascular risk, it’s not just about wanting to lose a few kilos. Sometimes it’s a medical lever capable of altering a risk trajectory. The moral disdain around these treatments is often unfair. But the opposite myth—believing everyone should have universal access as a solution—is equally naive. A powerful medication requires indication, monitoring, nutritional strategy, reflection on muscle mass, and anticipation of what comes after.

This is precisely where a personalized approach becomes indispensable. Two people can receive the same medication, lose the same number of kilos, but not build the same body. The first increases protein intake, maintains resistance training, stabilizes sleep, reduces ultra-processed foods, understands satiety signals, and gradually escapes metabolic chaos. The second simply eats much less, loses muscle, moves little, digests poorly, sleeps badly, then regains weight as the pharmacological signal fades. On the scale, both may seem to have “succeeded” initially. Biologically, these are very different stories.

GLP-1 thus forces us to revisit a question often avoided in dieting: are we only trying to lower a number, or to restore functional capacity? Because a body that depends on an external signal not to collapse into cravings is sending information. A body that never feels satiety without medication is sending information. A body that quickly regains weight after stopping is sending information. A body that loses weight but loses strength is sending information. The problem is not just the treatment. The problem is how we interpret what happens during treatment.

Within the carnivore or low-carb framework, this interpretation becomes even more interesting. Many people arrive at GLP-1 after years of frequent carbs, processed foods, snacking, fatigue, unstable hunger, and repeated failures. For some, drastically reducing carbs, increasing nutritional density, eating more animal protein, and eliminating hyperpalatable foods can already profoundly change hunger. For others, this won’t be enough or immediate. Why? Because the terrain is not only dietary. It can be nervous, digestive, hormonal, inflammatory, muscular, behavioral, or related to sleep.

That’s why we must move beyond simplistic battles: “GLP-1 or willpower,” “medication or natural,” “carnivore or injection.” The real discussion is more nuanced. A GLP-1 agonist can be medically relevant in some cases. A carnivore or low-carb approach can clarify food signals and stabilize the terrain. Training can be essential to preserve lean mass. Sleep can determine next-day hunger. Stress can sabotage glycemia. Digestion can limit tolerance to fat or protein. And neuroprofile can influence how a person reacts to restriction, routine, frustration, food reward, or pressure.

What we know today is this: GLP-1 is a real, powerful, biologically central signal. Drugs targeting this system have changed the management of obesity, type 2 diabetes, and several metabolic complications. They are not an illusion. They are not just a trend. They are not a panacea either. Results in neurodegeneration, for example, remain mixed: recent reviews emphasize that GLP-1 agonists are not indicated for Alzheimer’s or Parkinson’s outside trials, despite interesting preclinical and epidemiological signals.

What research is working on now is the next layer: better targeting patients, combining hormonal pathways, developing simpler oral forms, understanding effects on brain, liver, kidneys, heart, inflammation, addictions, and especially identifying who responds, who doesn’t, who tolerates, who regains, who loses too much muscle, who needs stricter nutritional support, and who should first correct their terrain before seeking a pharmacological lever.

Here lies the true frontier of GLP-1: it’s no longer just about whether it works. It’s about for whom, why, how far, at what cost, and with what surrounding strategy.

The final, most subtle myth would be to believe that because science advances, the individual can disappear behind the molecule. It’s the opposite. The more powerful the tools become, the more important the individual terrain is. GLP-1 can reduce noise. But once the noise is reduced, one question remains: what does the silence reveal?

At this stage, the real question is no longer to read one more piece of advice about GLP-1, carnivore, low carb, or weight loss. The real question is to understand what applies to your case: your dietary history, your hunger, your stress, your sleep, your digestion, your muscle mass, your relationship with carbs, your athletic level, and your real capacity to maintain results.

Are you still looking for a molecule, a method, or a general rule—or is your body finally asking for a precise reading of your own terrain?

Understanding My Metabolic Terrain

#GLP1 #LowCarb #Carnivore #Obesity #Insulin #Metabolism #Satiety #Type2Diabetes #WeightLoss #MetabolicHealth #AthleticCarnivore